Caverion Corporation’s Annual General Meeting was held on 28 March 2022 in Helsinki under the so-called Temporary Act (375/2021) without the shareholders’ or their proxy representatives’ presence at the meeting venue. The Annual General Meeting adopted the Financial Statements and the consolidated Financial Statements for the year 2021 and discharged the members of the Board of Directors and the President and CEOs from liability. In addition, the Annual General Meeting resolved on the use of the profit shown on the balance sheet and the payment of dividend, the approval of the presented Remuneration Report for Governing Bodies, on the composition of members of the Board of Directors and their remuneration, the election of the auditor and its remuneration as well as authorised the Board of Directors to decide on the repurchase of the Company’s own shares and/or acceptance as pledge of own shares as well as share issues.
The Annual General Meeting approved the proposal of the Board of Directors according to which a dividend of EUR 0.17 per share will be paid from the distributable funds of the Company for the financial year 2021. The dividend will be paid to shareholders who on the record date of the dividend payment 30 March 2022 are recorded in the shareholders’ register held by Euroclear Finland Oy. The dividend shall be paid on 6 April 2022.
Composition of the Board of Directors
The Annual General Meeting elected a Chairman, a Vice Chairman and five (5) ordinary members to the Board of Directors. Mats Paulsson was elected as the Chairman of the Board of Directors, Markus Ehrnrooth as the Vice Chairman and Jussi Aho, Joachim Hallengren, Thomas Hinnerskov, Kristina Jahn and Jasmin Soravia as members of the Board of Directors for a term of office expiring at the end of the Annual General Meeting 2023.
Remuneration to be paid to the Board of Directors
The Annual General Meeting decided that the annual fees for the members of the Board of Directors remain unchanged and that the following annual fees will be paid:
Approximately 40% of the annual remuneration will be paid in Caverion Corporation’s shares. The shares will be purchased directly at market price on behalf of the board members from a regulated market’s public trading. The shares shall be purchased within two (2) weeks of the publication of the interim report for the period 1 January–31 March 2022. The board member is not allowed to sell or transfer ownership of the purchased shares and for securing this a transfer restriction of two (2) years from the date of purchase of the shares will be placed on the shares. However, if the membership in the Board of Directors terminates earlier, the transfer restriction ceases at the termination.
In addition, EUR 900 per meeting shall be paid to each member of the Board of Directors for their participation in meetings of the Board of Directors and its committees in addition to the annual remuneration. Possible travel expenses are reimbursed in accordance with the principles related to remuneration of tax-exempt travel expenses approved by the Finnish Tax Administration.
Election of the auditor and its remuneration
Authorised Public Accountants Ernst & Young Oy was re-elected as auditor of the Company for a term of office expiring at the end of the Annual General Meeting 2023. The auditor’s remuneration will be paid according to invoice approved by the Company.
Repurchase and/or acceptance as pledge of own shares
The Annual General Meeting authorised the Board of Directors to decide on the repurchase and/or on the acceptance as pledge of the Company’s own shares in accordance with the proposal by the Board of Directors.
The total number of own shares to be repurchased and/or accepted as pledge shall not exceed 13,500,000 shares, which corresponds to approximately 9.7% of all the shares in the Company. The Company may use only unrestricted equity to repurchase own shares on the basis of the authorization.
Purchase of own shares may be made at a price formed in public trading on the date of the repurchase or otherwise at a price formed on the market.
The Board of Directors resolves on the manner in which own shares will be repurchased and/or accepted as pledge. Repurchase of own shares may be made using, inter alia, derivatives. The repurchase and/or acceptance as pledge of own shares may be made otherwise than in proportion to the share ownership of the shareholders (directed repurchase or acceptance as pledge).
The authorization cancels the authorization given by the Annual General Meeting on 24 March 2021 to decide on the repurchase and/or acceptance as pledge of the Company’s own shares.
The authorization is valid until 28 September 2023.
The Annual General Meeting authorised the Board of Directors to decide on share issues in accordance with the proposal by the Board of Directors.
The total number of shares to be issued under the authorization may not exceed 13,500,000 shares, which corresponds to approximately 9.7% of all the shares in the Company.
The Board of Directors decides on all the conditions of the issuance of shares. The authorization concerns both the issuance of new shares as well as the transfer of treasury shares. The issuance of shares may be carried out in deviation from the shareholders’ pre-emptive rights (directed issue). The authorization can be used, e.g. in order to develop the Company’s capital structure, to broaden the Company’s ownership base, to be used as payment in corporate acquisitions or when the Company acquires assets relating to its business and as part of the Company’s incentive programs.
The authorization cancels the authorization given by the Annual General Meeting on 24 March 2021 to decide on the issuance of shares.
The authorization is valid until the end of the next Annual General Meeting, however no later than 30 June 2023.
Decisions of the Board of Directors on the composition of its committees
Convening after the Annual General Meeting the Board of Directors appointed from among its members the following members to its committees:
Notice of the meeting (pdf)
includes agenda, proposed members of the board and proposals to AGM
Question: Will Caverion reach the same profitability level as Bravida?
In terms of profitability, Caverion’s mid-term financial target is adjusted EBITA > 5.5% of revenue. Adjusted EBITA margin was 4.1% in 2021. According to the guidance published in connection with our financial statements release on 10 February 2022, Caverion Group’s revenue (2021: EUR 2,139.5 million) and adjusted EBITA (2021: EUR 87.7 million) will grow in 2022 compared to 2021. We do not comment on other companies’ figures, they are always company specific. We will target sustainable profitable growth going forward. We strongly believe in our purpose to enable building performance and people’s wellbeing in smart and sustainable built environment.